Title : Adverse reactions combination therapy MDR-TB using Bedaquiline
Abstract:
Since 2013, the Russian Federation has been using the new anti-TB drug Bedaquiline (Sirturo), whose mechanism of action is radically different from the existing anti-TB drugs. The drug has shown its high effectiveness in the treatment of drug resistant tuberculosis. In phase III clinical trials, the bedaquiline group showed a significant increase in the number of deaths without an obvious causal factor, compared with the placebo group (12.7 vs. 2.5%). Despite the high efficacy of bedaquiline, community CRAG experts expressed concerns about the safety of the drug and said that more information on the safety of Bedaquiline was urgently needed.
